[go: up one dir, main page]

EA201992801A1 - Способ получения соединения гетероциклического производного, композиции, содержащей указанное соединение, и гидрата указанного соединения - Google Patents

Способ получения соединения гетероциклического производного, композиции, содержащей указанное соединение, и гидрата указанного соединения

Info

Publication number
EA201992801A1
EA201992801A1 EA201992801A EA201992801A EA201992801A1 EA 201992801 A1 EA201992801 A1 EA 201992801A1 EA 201992801 A EA201992801 A EA 201992801A EA 201992801 A EA201992801 A EA 201992801A EA 201992801 A1 EA201992801 A1 EA 201992801A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compound
hydrate
producing
heterocyclic derivative
specified compound
Prior art date
Application number
EA201992801A
Other languages
English (en)
Inventor
До Киу Пиун
Киоунг Дзин ОО
Original Assignee
Джей ДаблЮ ФАРМАСЬЮТИКАЛ КОРПОРЭЙШН
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Джей ДаблЮ ФАРМАСЬЮТИКАЛ КОРПОРЭЙШН filed Critical Джей ДаблЮ ФАРМАСЬЮТИКАЛ КОРПОРЭЙШН
Publication of EA201992801A1 publication Critical patent/EA201992801A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
    • C07C63/04—Monocyclic monocarboxylic acids
    • C07C63/06—Benzoic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
    • C07C63/04—Monocyclic monocarboxylic acids
    • C07C63/06—Benzoic acid
    • C07C63/10—Halides thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/96—Esters of carbonic or haloformic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Настоящее изобретение относится к новому способу получения соединения гетероциклического производного химической формулы I; к новому промежуточному соединению, используемому в способе получения; к композиции для лечения или предупреждения гиперурикемии, подагры, нефрита, хронической почечной недостаточности, нефролитиаза, уремии, уролитиаза или заболевания, ассоциированного с мочевой кислотой, которая содержит соединение формулы I в дозе от более чем 2 до 10 мг или менее и вводится перорально один раз в сутки; и к 1,5-гидрату (сесквигидрату) гидрохлорида нового соединения химической формулы I.
EA201992801A 2017-05-25 2018-05-24 Способ получения соединения гетероциклического производного, композиции, содержащей указанное соединение, и гидрата указанного соединения EA201992801A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20170064914 2017-05-25
PCT/KR2018/005932 WO2018217050A1 (ko) 2017-05-25 2018-05-24 헤테로사이클 유도체 화합물의 제조방법, 상기 화합물을 포함하는 조성물 및 상기 화합물의 수화물

Publications (1)

Publication Number Publication Date
EA201992801A1 true EA201992801A1 (ru) 2020-03-19

Family

ID=64396846

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201992801A EA201992801A1 (ru) 2017-05-25 2018-05-24 Способ получения соединения гетероциклического производного, композиции, содержащей указанное соединение, и гидрата указанного соединения

Country Status (25)

Country Link
US (5) US20200207784A1 (ru)
EP (3) EP3909955A1 (ru)
JP (4) JP2020521007A (ru)
KR (1) KR102307504B1 (ru)
CN (3) CN119143779A (ru)
AU (1) AU2018273020B2 (ru)
CA (2) CA3061301C (ru)
DK (1) DK3909956T3 (ru)
EA (1) EA201992801A1 (ru)
ES (2) ES3011357T3 (ru)
FI (1) FI3909956T3 (ru)
HR (1) HRP20250183T1 (ru)
HU (1) HUE070148T2 (ru)
IL (2) IL294127B2 (ru)
LT (1) LT3909956T (ru)
MX (2) MX393863B (ru)
MY (1) MY201054A (ru)
NZ (2) NZ758513A (ru)
PH (1) PH12019502418B1 (ru)
PL (2) PL3909956T3 (ru)
PT (1) PT3909956T (ru)
SI (1) SI3909956T1 (ru)
TW (2) TW202411234A (ru)
WO (1) WO2018217050A1 (ru)
ZA (1) ZA201908433B (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021087836A (ja) * 2021-03-01 2021-06-10 株式会社三洋物産 遊技機
JP2021079225A (ja) * 2021-03-01 2021-05-27 株式会社三洋物産 遊技機
JP7556433B2 (ja) * 2022-08-22 2024-09-26 株式会社三洋物産 遊技機
JP7556432B2 (ja) * 2022-08-22 2024-09-26 株式会社三洋物産 遊技機
JP7556434B2 (ja) * 2022-08-22 2024-09-26 株式会社三洋物産 遊技機

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6197291A (ja) * 1984-10-17 1986-05-15 Yamanouchi Pharmaceut Co Ltd ７−〔α−（２−アミノ−４−チアゾリル）−α−（低級アルコキシイミノ）アセトアミド〕−３−〔６−（２Ｈ−ピリド〔４，３−ｂ〕−１，４−オキサジニオ）メチル〕−Δ３−セフエム−４−カルボキシレ−トおよびその製造法
IL119466A (en) 1995-11-03 2001-08-26 Akzo Nobel Nv Thrombin inhibitors, their preparation and pharmaceutical compositions containing them
AR051780A1 (es) * 2004-11-29 2007-02-07 Japan Tobacco Inc Compuestos en anillo fusionados que contienen nitrogeno y utilizacion de los mismos
JP3988832B2 (ja) * 2004-11-29 2007-10-10 日本たばこ産業株式会社 窒素含有縮合環化合物及びその用途
JP4646068B2 (ja) * 2005-09-30 2011-03-09 国立大学法人東京工業大学 ポジ型感光性樹脂組成物、その製造方法、及びレリーフパターンの形成方法
US20080305169A1 (en) * 2006-05-26 2008-12-11 Japan Tobacco Inc. Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds
US20080064871A1 (en) * 2006-05-26 2008-03-13 Japan Tobacco Inc. Production Method of Nitrogen-Containing Fused Ring Compounds
WO2008062740A1 (fr) * 2006-11-20 2008-05-29 Japan Tobacco Inc. Composé azoté à anneaux fusionnés et son utilisation
BRPI0909691B1 (pt) * 2008-03-31 2021-07-20 C&C Research Laboratories Composto derivado de heterociclo, método para preparar um composto, e, composição farmacêutica
EP2281128B1 (en) * 2008-04-28 2019-08-28 Robert Bosch GmbH Drive belt ring component and manufacturing method and maraging steel base material therefor

Also Published As

Publication number Publication date
PL3909956T3 (pl) 2025-04-07
NZ780383A (en) 2025-12-19
JP2022126729A (ja) 2022-08-30
MY201054A (en) 2024-01-31
US20200207784A1 (en) 2020-07-02
CA3150710C (en) 2023-10-10
CN114085235B (zh) 2024-08-13
US20240083911A1 (en) 2024-03-14
IL294127A (en) 2022-08-01
US12497410B2 (en) 2025-12-16
HRP20250183T1 (hr) 2025-04-11
CN110691783A (zh) 2020-01-14
PH12019502418A1 (en) 2020-07-06
SI3909956T1 (sl) 2025-04-30
PT3909956T (pt) 2025-02-21
EP3909956A1 (en) 2021-11-17
ZA201908433B (en) 2021-04-28
IL294127B2 (en) 2024-07-01
EP3632917A4 (en) 2020-07-01
IL270789A (en) 2020-01-30
IL270789B2 (en) 2023-09-01
TW201900652A (zh) 2019-01-01
EP3632917B1 (en) 2021-11-17
AU2018273020B2 (en) 2020-10-15
KR102307504B1 (ko) 2021-09-30
JP2024129160A (ja) 2024-09-26
US11866448B2 (en) 2024-01-09
EP3909956B1 (en) 2024-12-04
JP7557500B2 (ja) 2024-09-27
ES2907590T3 (es) 2022-04-25
LT3909956T (lt) 2025-03-10
MX393863B (es) 2025-03-21
TWI837089B (zh) 2024-04-01
US12103938B2 (en) 2024-10-01
JP2024129161A (ja) 2024-09-26
EP3909955A1 (en) 2021-11-17
HUE070148T2 (hu) 2025-05-28
CA3061301A1 (en) 2019-10-23
JP2020521007A (ja) 2020-07-16
JP7796815B2 (ja) 2026-01-09
CA3150710A1 (en) 2019-10-23
TW202411234A (zh) 2024-03-16
MX2022005722A (es) 2022-06-09
US20220363691A1 (en) 2022-11-17
IL294127B1 (en) 2024-03-01
FI3909956T3 (fi) 2025-02-21
KR20190132693A (ko) 2019-11-28
US12030895B2 (en) 2024-07-09
CN114085235A (zh) 2022-02-25
PL3632917T3 (pl) 2022-04-11
CA3061301C (en) 2022-05-31
CN119143779A (zh) 2024-12-17
US20220340594A1 (en) 2022-10-27
PH12019502418B1 (en) 2023-12-06
EP3632917A1 (en) 2020-04-08
WO2018217050A1 (ko) 2018-11-29
IL270789B1 (en) 2023-05-01
NZ758513A (en) 2022-02-25
BR112019024253A2 (pt) 2020-06-02
AU2018273020A1 (en) 2019-11-14
ES3011357T3 (en) 2025-04-07
MX2019013937A (es) 2020-02-07
US20240067659A1 (en) 2024-02-29
DK3909956T3 (da) 2025-03-03

Similar Documents

Publication Publication Date Title
EA201992801A1 (ru) Способ получения соединения гетероциклического производного, композиции, содержащей указанное соединение, и гидрата указанного соединения
SA521431048B1 (ar) مركبات بيروليدين
EA201000341A1 (ru) 2-анилинопурин-8-оны в качестве ингибиторов ttk/mps1 для лечения пролиферативных нарушений
NO20083568L (no) Hydantoinforbindelser for behandling av inflammatoriske forstyrrelser
EA200970611A1 (ru) Замещенные пиразолохиназолиновые производные, способ их получения и их применение в качестве ингибиторов киназы
NO20083868L (no) IAP BIR domenebindende forbindelser
MX2009008953A (es) Compuestos como inhibidores de angiogenesis.
EA201100503A1 (ru) Глюкозидные производные и их применения
EA201492170A1 (ru) Новые замещенные в цикле n-пиридиниламиды в качестве ингибиторов киназ
NO20084363L (no) 2-Substituerte 4-benzylftalazinonderivater som histamin H1- og H3-antagonister
BR112021023153A2 (pt) Compostos de pirazol dissubstituídos como inibidores de ceto-hexoquinase
EA201990902A1 (ru) Ингибиторы тирозинкиназы брутона
EA201000120A1 (ru) Фармацевтические композиции, содержащие холиновые соли янтарной кислоты, для интраназального введения
NO20074084L (no) Substituerte 4-fenyltetrahydroisokinoliner, fremgangsmate for fremstilling derav, deres anvendelse som medikamenter og medikamenter inneholdende disse
EA202192900A1 (ru) Модуляторы пути интегрированной реакции на стресс
NO20054876L (no) Substituerte 4-fenyltetrahydroisokinoliner, fremgangsmate for fremstilling derav, deres anvendelse som medikament og medikament inneholdende slike forbindelser
EA201071269A1 (ru) 3,4-замещенные пиперидиновые производные в качестве ингибиторов ренина
CR20240183A (es) Inhibidores y/o degradadores de bckdk
EA200970170A1 (ru) Производные 4-триметиламмоний-3-аминобутирата и 4-триметилфосфоний-3-аминобутирата как ингибиторы срт
EA201100502A1 (ru) Гликозидные производные и их применения
NO20063865L (no) Heterocyklisk substituerte 7-amino-4-kinolon-3-karboksylsyrederivater, fremgangsmate for fremstilling derav og deres anvendelse som medikamenter
JP2017537104A (ja) 変形性関節症におけるσ受容体リガンドの使用
CN108601784A (zh) 药物
PE20240242A1 (es) Una composicion farmaceutica que comprende acido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxilico
EA201000882A1 (ru) Соединение, его применение и фармацевтическая композиция, содержащая это соединение